SynOx Therapeutics’ Post

Research analysts at Germany’s Sphene Capital GmbH estimated that each Vidac Pharma share represents a value of €4.90, initiating coverage of the shares with a Buy rating. The valuation – which represents vast upside from where the stock is trading today – is based on the assumption that Vidac will obtain market approval for VDA-1102, its most advanced therapeutic candidate, for actinic keratosis. “If the market entry with VDA-1102 succeeds in 2027 as we expect, we assume that the company will achieve profitability ratios like comparable pharmaceutical companies in a very short time,” the analysts said their 75-page strong report. Other points making Vidac attractive were its two-product pipeline, being a pioneer in treating actinic keratosis with the toposteric effect, application across a wide range of tumors, a stable shareholder structure, and a clear undervaluation by the market. To read the full report, go to our website: https://lnkd.in/da-3wkFm #cancer #biotech #onchology #science #vidacpharma

💊 🔬 Join KCAS Bio for an enlightening webinar as we explore the expanding role of hybrid LC-MS/MS in ADC analysis. Discover how this innovative approach offers flexibility and multiple advantages, allowing for the simultaneous monitoring of total antibodies and ADCs, irrespective of conjugation type or linker used. From oncology to novel modalities like antibody-peptide conjugates and antibody-RNA conjugates (ARCs), hybrid LC-MS/MS is reshaping the landscape of drug development. Don't miss this opportunity to gain insights from Dawn Dufield into the transformative potential of hybrid LC-MS/MS and enhance your bioanalytical capabilities. ➡️ REGISTER HERE: https://buff.ly/4aMa6wF #DrugDevelopment #Biosimilars #Bioanalytical #MassSpectrometry #LaboratoryTechnology #LiquidChromatography #BioanalyticalTesting

#ADCs are currently super-hot molecules right now, attracting intense competition in the #dealmaking landscape, sky-high #valuations and sparking interest for their potential applications beyond #cancer treatment.   🎯 Key Insights from the Article: - ADCs outperform traditional chemotherapy across multiple indications. - #Revenue from approved ADCs and those in Ph III development is projected to reach $26 billion in 2028. - Challenges remain: limited validated payload #MoAs and non-specific/ insufficient #payload delivery. 🔍 Current ADC clinical #pipeline: - Type-1 Assets: 75% Ph I/II ADCs have new targets and/or payload MoAs with first-in-class potential. - Type-2 Assets: 60% Ph III ADCs are leveraging established target/payload MoAs combinations with novel delivery components to achieve best-in-class profile.   🚀 Next-Generation ADCs: - Next-gen #targets: 61 unique biological targets under #clinical investigation, with 10% targets associated to #TME. - Next-gen #technology with innovative & novel #payloads, #carriers, #linkers, and #conjugation 🌐 Read the full article: doi: https://lnkd.in/d6X9Whf8 #pharmainnovation #pharmaceuticalinnovation #biotechinnovation #biopharma #healthcareinnovation #antibodydrugconjugates

Antibody-drug conjugates (ADCs) are trumping all other drug classes in the #oncology market. With big #pharma playing their best cards, investments have surged to nearly $100 billion in 2023. Explore the ultimate #ADC showdown, featuring a deck of key players as well as rising biotechs with promising programmes and the potential to advance to the next level. Read the #report here: https://lnkd.in/emnaEkGq

🔬 We will be attending the 6th Macrophage-Directed Therapies Summit 2024 in Boston, MA from October 1-3, 2024! 👉 https://lnkd.in/ejDm6xDJ On Thursday, October 3, 2024 at 9:30 a.m. EDT, Kader Thiam, our Senior Vice President - Discovery, Preclinical Models and Services, will give a presentation titled "How to enhance translatability of myeloid-targeted therapies in preclinical models" The presentation will focus on: ▶ #BRGSF-HIS mouse: the only CD34+-reconstituted model with functional human lymphoid and myeloid compartments without side effects ▶ Myeloid cells functionality and assessment of immune modulation induced by biologics in the model ▶ Safety studies in the BRGSF-HIS model to investigate immune-related adverse effects Read more on the BRGSF-HIS model here 👉 https://lnkd.in/eUav-Ra5 #macrophagedirectedtherapiessummit #preclinicalmodels #cancerresearch 

VHH/single-domain antibodies are revolutionizing research, therapeutics, and diagnostics. VHH have several advantages over conventional antibodies due to their smaller size and easier engineering. In our latest whitepaper, learn how the VHH discovery process works from the experts at Abcore and the many applications of these single-domain antibodies. Download full whitepaper here: https://lnkd.in/g_vEB53h Preview a sample below ⤵️ #VHH #SingleDomainAntibodies #CustomAntibodies #AntibodyDiscovery #Biopharma #Innovation #Therapeutics #PrecisionMedicine #TargetedTherapies #DrugDiscovery #DrugDevelopment #Whitepaper #AppNote

ANGLE says targets turning cash flow positive after first half hiccup @parsortix #AIM #OTCQX #AGL #ANPCY. ANGLE PLC (AIM:AGL, OTCQX:ANPCY), the med-tech group, told investors that it will likely be cash flow positive in the second half of 2026 as it provided an upbeat assessment of prospects.  In commentary alongside its interims, it said it is seeing encouraging momentum as it builds a pipeline of major pharmaceutical and corporate partnerships. The company’s product, Parsortix, a liquid biopsy tool designed to aid cancer diagnosis, is gaining traction, with several high-profile agreements in place that could lead to large-scale revenue growth. Three major... http://ow.ly/chkb105JWkn

Antibody-drug conjugates (ADCs) are the hottest real estate in oncology, attracting billions from big pharma 👉 Wondering what all the fuss is about and why would-be investors are priced out of the market? 👉 Read our report now for insights on the market landscape, including complexities in the field and key deal drivers. Find out who’s top of the pile and who’s poised to make the next move. Evaluate Ltd Norstella #antibodies #antibody #antibodydiscovery #antibodydrugconjugates #pharma #biopharma #drugdevelopment #bigpharma

𝐅𝐨𝐫𝐦𝐲𝐜𝐨𝐧 𝐬𝐭𝐚𝐫𝐭𝐬 𝐜𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐝𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭 𝐩𝐫𝐨𝐠𝐫𝐚𝐦 𝐟𝐨𝐫 𝐅𝐘𝐁𝟐𝟎𝟔, 𝐚 𝐛𝐢𝐨𝐬𝐢𝐦𝐢𝐥𝐚𝐫 𝐜𝐚𝐧𝐝𝐢𝐝𝐚𝐭𝐞 𝐟𝐨𝐫 𝐢𝐦𝐦𝐮𝐧𝐨-𝐨𝐧𝐜𝐨𝐥𝐨𝐠𝐲 𝐛𝐥𝐨𝐜𝐤𝐛𝐮𝐬𝐭𝐞𝐫 𝐝𝐫𝐮𝐠 𝐊𝐞𝐲𝐭𝐫𝐮𝐝𝐚® (𝐏𝐞𝐦𝐛𝐫𝐨𝐥𝐢𝐳𝐮𝐦𝐚𝐛) “With the start of the clinical development program and the first patient in, we have reached a major #milestone. We are at the forefront of the development of a #pembrolizumab biosimilar. Our FYB206 project not only has immense commercial potential, but above all offers exceptional therapeutic options.”, commented Dr. Stefan Glombitza, CEO of Formycon AG. With the 𝐟𝐢𝐫𝐬𝐭 𝐩𝐚𝐭𝐢𝐞𝐧𝐭 𝐢𝐧 the Phase I clinical #trial, Formycon is among the first three biosimilar companies announcing entry into the #clinical #development phase for the #EU and #US market. For further #details, please check our corporate news published today: https://lnkd.in/eDBhBrUm #TeamFormycon #FYB206 #Biosimilar #PK #PD1 #Oncology

Whether it is fed-batch or perfusion processes for the commercial manufacture of biomolecule therapeutics, identifying an appropriate medium for your cell culture process is key for successful scale-up and manufacture. R&D Production Manager – Bioproduction, Luis Rodriguez, PhD, presents on how efficient production of monoclonal antibodies in CHO cells requires optimized cell culture solutions upstream. Below is the link to the webinar recording. https://lnkd.in/eZPH5w35